ESR1 and cancer: This phenomenon may be attributed to the fact that ESR1+ patients exhibit significant responsiveness to tamoxifen [45], and cancer women with ESR1 amplification showed significantly prolonged survival following adjuvant tamoxifen monotherapy [46].